High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. (Q40044204)

16 September 2017

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. (English)

1 reference

16 September 2017

1 reference

lymphoblastic leukemia

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Shigeki Ohtake

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Yukio Kobayashi

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Keitaro Matsuo

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

T Sakura

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

F Hayakawa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

I Sugiura

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

T Murayama

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

K Imai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

N Usui

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

S Fujisawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

T Yamauchi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

K Kakihana

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Y Ito

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

H Kanamori

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Y Ueda

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Y Miyata

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

M Kurokawa

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

N Asou

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

K Ohnishi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

H Kiyoi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Y Miyazaki

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

T Naoe

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

15 September 2017

1 reference

16 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

626-632

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28914260%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2017.283

13 June 2020

exact match

0 references

cites work

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

High-dose methotrexate in childhood all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

7 January 2021

inferred from DOI database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

7 January 2021

inferred from DOI database lookup

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.283

7 January 2021

inferred from DOI database lookup

Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications

1 reference

12 December 2020

Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report

1 reference

12 December 2020

Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update)

1 reference

12 December 2020

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group

1 reference

12 December 2020